SG11201911527QA - Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa - Google Patents

Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa

Info

Publication number
SG11201911527QA
SG11201911527QA SG11201911527QA SG11201911527QA SG11201911527QA SG 11201911527Q A SG11201911527Q A SG 11201911527QA SG 11201911527Q A SG11201911527Q A SG 11201911527QA SG 11201911527Q A SG11201911527Q A SG 11201911527QA SG 11201911527Q A SG11201911527Q A SG 11201911527QA
Authority
SG
Singapore
Prior art keywords
hsa
hetero
specific antibody
antibody format
dimeric multi
Prior art date
Application number
SG11201911527QA
Other languages
English (en)
Inventor
David Urech
Tea Gunde
Sebastian Meyer
Christian Hess
Alexandre Simonin
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of SG11201911527QA publication Critical patent/SG11201911527QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201911527QA 2017-06-05 2018-06-04 Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa SG11201911527QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515293P 2017-06-05 2017-06-05
PCT/EP2018/064633 WO2018224443A1 (en) 2017-06-05 2018-06-04 Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa

Publications (1)

Publication Number Publication Date
SG11201911527QA true SG11201911527QA (en) 2020-01-30

Family

ID=60473421

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911527QA SG11201911527QA (en) 2017-06-05 2018-06-04 Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa

Country Status (10)

Country Link
US (1) US20200181263A1 (zh)
EP (1) EP3635014B1 (zh)
KR (1) KR20200013230A (zh)
CN (1) CN110719918B (zh)
AU (1) AU2018280683A1 (zh)
CA (1) CA3065868C (zh)
ES (1) ES2967739T3 (zh)
MA (1) MA49255A (zh)
SG (1) SG11201911527QA (zh)
WO (1) WO2018224443A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634998A1 (en) * 2017-06-05 2020-04-15 Numab Therapeutics AG Novel anti-cd3 antibodies
BR112020020919A2 (pt) 2018-04-13 2021-04-06 Sangamo Therapeutics France Receptor de antígeno quimérico específico para receptor de interleucina-23
CA3120800A1 (en) * 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
SG11202107995SA (en) * 2019-01-31 2021-08-30 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3808766A1 (en) * 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
EP3915580A1 (en) * 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
WO2022167460A1 (en) * 2021-02-02 2022-08-11 Numab Therapeutics AG Multispecific antibodies having specificity for ror1 and cd3
CN117003872A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
WO2024135812A1 (en) * 2022-12-23 2024-06-27 Chugai Seiyaku Kabushiki Kaisha A polypeptide complex whose antigen-binding activity varies depending on the concentration of a plasma protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0859841T3 (da) 1995-08-18 2002-09-09 Morphosys Ag Protein/(poly)peptidbiblioteker
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
EP3916011A1 (en) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
BR112014001573B8 (pt) * 2011-07-22 2022-11-08 Affimed Therapeutics Ag Molécula fv ao antígeno multivalente
CN113943366A (zh) 2013-06-26 2022-01-18 努玛医疗技术有限公司 新型抗体框架
WO2015058861A1 (en) 2013-10-25 2015-04-30 Numab Ag Bispecific constructs and their use in the treatment of various diseases
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules
WO2016184570A1 (en) * 2015-05-18 2016-11-24 Numab Ag Novel treatment methods based on multifunctional molecules
CA2989474C (en) 2015-06-15 2023-09-05 Numab Innovation Ag Hetero-dimeric multi-specific antibody format
EP3634998A1 (en) * 2017-06-05 2020-04-15 Numab Therapeutics AG Novel anti-cd3 antibodies
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体

Also Published As

Publication number Publication date
ES2967739T3 (es) 2024-05-03
CA3065868C (en) 2024-06-04
KR20200013230A (ko) 2020-02-06
EP3635014C0 (en) 2023-09-27
AU2018280683A1 (en) 2019-10-17
MA49255A (fr) 2020-04-15
WO2018224443A1 (en) 2018-12-13
CN110719918B (zh) 2024-05-24
CN110719918A (zh) 2020-01-21
US20200181263A1 (en) 2020-06-11
EP3635014B1 (en) 2023-09-27
CA3065868A1 (en) 2018-12-13
EP3635014A1 (en) 2020-04-15
JP2020522267A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
SG11201911527QA (en) Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
HK1245805A1 (zh) 雜二聚體多特異性抗體形式
ZA202203250B (en) Cd3 binding antibodies
HK1248250A1 (zh) 連接中皮素和cd3的雙特異性抗體構建體
IL263840A (en) cd3 binding antibodies
IL259643A (en) Antibodies and antibody fragments for site-specific conjugation
EP3186279C0 (en) ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
DK3223845T3 (da) Heterodimere antistoffer, der binder cd3 og cd20
ZA201506129B (en) Antibody constructs for cdh19 and cd3
ZA201908072B (en) Igf-1r monoclonal antibodies and uses thereof
HK1256816A1 (zh) 新型抗人gpvi抗體及其用途
IL279399A (en) Multispecific antibody templates
IL258534A (en) Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
GB201511196D0 (en) Monoclonal antibodies
GB201709535D0 (en) IL-11 Antibodies
GB201621446D0 (en) IL-11 antibodies